Regeneron Secures $400 Million Victory in Landmark Antitrust Ruling Against Amgen
Bridgewater, New Jersey — A jury has awarded Regeneron Pharmaceuticals Inc. $400 million in a significant antitrust case against rival Amgen Inc. This landmark decision underscores the ongoing legal battles over market competition and patent rights in the biotechnology sector. The case revolved around claims that Amgen engaged in anti-competitive practices that harmed Regeneron’s business interests. The jury’s verdict reinforces Regeneron’s position, alleging that Amgen’s actions restricted the market and competitive landscape for vital medications. Both companies are significant players in the pharmaceutical industry, with a focus on cutting-edge treatments. Regeneron, known for its work … Read more